GB Sciences (GBLX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for Q3 FY2025, filed Aug 12, 2025. Each column of the statement tables below links to the filing it was taken from.
GB Sciences Inc (GBLX) reported $97K in revenue over the twelve months to Dec 31, 2024. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
GB Sciences’ reported footprint has shrunk sharply while liabilities remain elevated, leaving a balance sheet with little current-asset coverage.
From FY2022 to FY2024, total assets fell95.9% while total liabilities rose25.0% , shifting the balance sheet toward obligations rather than operating resources. The current ratio also moved from 0.1x to 0.0x, indicating that near-term assets became progressively less able to cover near-term liabilities.
In FY2020, SG&A of
Operating cash flow was
Financial Health Signals
We do not publish a peer-relative financial health score for GB Sciences Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
GB Sciences Inc generated $97K in revenue in Q3 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
GB Sciences Inc's EBITDA was -$67K in Q3 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
GB Sciences Inc reported a net loss of $100K in Q3 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2025.
Cash & Balance Sheet
GB Sciences Inc held $3K in cash against $557K in long-term debt as of Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
GB Sciences Inc's gross margin was 100.0% in Q3 2025, indicating the percentage of revenue retained after direct costs.
GB Sciences Inc's operating margin was -68.5% in Q3 2025, reflecting core business profitability.
Not shown for Q3 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2025.
Capital Allocation
None of these metrics is reported for Q3 2025.
GBLX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | $97Kn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Cost of Revenue | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Gross Profit | $97Kn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| SG&A Expenses | $164K-30.0% | $158K-71.4% | $254K-4.1% | N/A | $234K-42.5% | $551K+99.9% | $265K-42.3% | $530K+17.4% |
| Operating Income | -$67Kn/m | -$158Kn/m | -$254Kn/m | N/A | -$234Kn/m | -$551Kn/m | -$265Kn/m | -$530Kn/m |
| EBITDA | -$67Kn/m | -$158Kn/m | -$254Kn/m | N/A | -$234Kn/m | -$551Kn/m | -$264Kn/m | N/A |
| Interest Expense | $34K-11.8% | $33K-23.4% | $31K-24.3% | N/A | $38K-7.7% | $43K+14.8% | $41K+5.8% | N/A |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Net Income | -$100Kn/m | -$191Kn/m | -$285Kn/m | N/A | -$187Kn/m | -$434Kn/m | -$273Kn/m | N/A |
| EPS (Basic) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | -$0.01n/m |
Not reported in any period shown, so not listed: R&D Expenses, EPS (Diluted), Diluted Shares (Avg).
GBLX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $94K-35.8% | $94K-60.0% | $91K-60.1% | $103K-70.6% | $147K-58.2% | $234K-92.5% | $229K-90.2% | $352K-86.2% |
| Current Assets | $94K-35.8% | $94K-60.0% | $91K-60.1% | $103K-66.6% | $147K-52.5% | $234K-73.3% | $229K+107.7% | $310K-5.6% |
| Cash & Equivalents | $3K-82.7% | $2K-97.8% | $0-100.0% | $12K-89.1% | $17K-84.1% | $105K-84.1% | $30K-45.1% | $110K-53.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $6.0M+19.6% | $5.9M+19.2% | $5.7M+15.7% | $5.4M+13.8% | $5.0M+4.9% | $4.9M+14.3% | $4.9M+9.0% | $4.8M+9.9% |
| Current Liabilities | $5.4M+10.1% | $5.4M+12.1% | $5.4M+9.7% | $5.1M+7.1% | $4.9M+3.4% | $4.9M+18.6% | $4.9M+18.9% | $4.8M+20.9% |
| Non-Current Liabilities | $557K+642.7% | $432K+476.0% | $322K+1188.0% | $322Kn/m | $75Kn/m | $75K-65.8% | $25K-93.7% | $0-100.0% |
| Long-Term Debt | $557K+642.7% | $432K+476.0% | $322K+1188.0% | $322Kn/m | $75Kn/m | $75K-65.8% | $25K-93.7% | $0-100.0% |
| Total Equity | -$5.9Mn/m | -$5.8Mn/m | -$5.6Mn/m | -$5.3Mn/m | -$4.8Mn/m | -$4.7Mn/m | -$4.7Mn/m | -$4.4Mn/m |
| Retained Earnings | -$110.6Mn/m | -$110.5Mn/m | -$110.4Mn/m | -$110.1Mn/m | -$109.6Mn/m | -$109.4Mn/m | -$109.0Mn/m | -$108.7Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
GBLX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$124Kn/m | -$108Kn/m | -$22Kn/m | -$252Kn/m | -$205Kn/m | -$413Kn/m | -$105Kn/m | -$220Kn/m |
| Depreciation & Amortization | $0n/m | $0n/m | $0-100.0% | $0n/m | $0-100.0% | $0-100.0% | $624-96.9% | $0-100.0% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | N/A |
| Investing Cash Flow | $0-100.0% | N/A | N/A | $0n/m | $85Kn/m | N/A | N/A | $0n/m |
| Financing Cash Flow | $125K+275.0% | $110K-56.4% | $10K-60.0% | $247K+342.9% | $33K+95.8% | $252K-79.8% | $25K-77.7% | $56Kn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
GBLX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -68.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -103.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -106.2%+21.1pp | -203.2%-17.8pp | -311.7%-192.5pp | N/A | -127.3%+0.1pp | -185.4%-175.4pp | -119.2%-97.9pp | N/A |
| Current Ratio | 0.020.0x | 0.020.0x | 0.020.0x | 0.020.0x | 0.030.0x | 0.05-0.2x | 0.050.0x | 0.070.0x |
| Asset Turnover | 1.03+1.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Note: Shareholder equity is negative (-$5.3M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where GB Sciences Inc Ranks
Frequently Asked Questions
GB Sciences Inc (GBLX) reported $0 in total revenue for fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
As of fiscal year 2024, GB Sciences Inc (GBLX) had $12K in cash and equivalents against $322K in long-term debt.
GB Sciences Inc (GBLX) had $103K in total assets as of fiscal year 2024, including both current and long-term assets.
GB Sciences Inc (GBLX) invested $262K in research and development during fiscal year 2024.
GB Sciences Inc (GBLX) had a current ratio of 0.02 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
GB Sciences Inc (GBLX) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $41K as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
GB Sciences Inc (GBLX) trades at 0.4x sales, its market capitalization divided by $97K revenue, trailing 12 months to December 31, 2024. The market capitalization is $41K as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
GB Sciences Inc (GBLX) has negative shareholder equity of -$5.3M as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.